Advertisement
Singapore markets close in 3 hours 54 minutes

  • Straits Times Index

    3,168.91
    -18.75 (-0.59%)
     

  • Nikkei

    37,110.49
    -969.21 (-2.55%)
     

  • Hang Seng

    16,184.02
    -201.85 (-1.23%)
     

  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     

  • Bitcoin USD

    62,325.06
    +593.74 (+0.96%)
     

  • CMC Crypto 200

    1,288.06
    +402.52 (+44.29%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Gold

    2,398.50
    +0.50 (+0.02%)
     

  • Crude Oil

    84.25
    +1.52 (+1.84%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • FTSE Bursa Malaysia

    1,551.42
    +6.66 (+0.43%)
     

  • Jakarta Composite Index

    7,063.10
    -103.72 (-1.45%)
     

  • PSE Index

    6,411.73
    -111.46 (-1.71%)
     

MacroGenics: 4Q Earnings Snapshot

Associated Press
Updated ·1-min read

ROCKVILLE, Md. (AP) _ MacroGenics Inc. (MGNX) on Tuesday reported a loss of $30.4 million in its fourth quarter.

On a per-share basis, the Rockville, Maryland-based company said it had a loss of 62 cents.

The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 71 cents per share.

The biopharmaceutical company posted revenue of $25.2 million in the period, which also beat Street forecasts. Four analysts surveyed by Zacks expected $10.7 million.

For the year, the company reported that its loss narrowed to $151.8 million, or $3.16 per share. Revenue was reported as $64.2 million.

ADVERTISEMENT

MacroGenics shares have risen 1% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $10.99, a decline of 49% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MGNX at https://www.zacks.com/ap/MGNX